Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19) is under clinical development by Stemedica Cell Technologies and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19) overview

Stem cell therapy is under development for the treatment of acute respiratory distress syndrome and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered through intravenous route. The therapeutic candidate comprises of allogeneic bone marrow-derived mesenchymal stem cells.

Stemedica Cell Technologies overview

Stemedica Cell Technologies, Inc (Stemedica) is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions. The company’s main products include ischemia-tolerant mesenchymal stem cells (itMSCs) and ischemia-tolerant neural progenitor cells (itNSCs), which are used in the treatment of ischemic stroke, Alzheimer’s disease, and spinal cord injury. Stemedica’s proprietary manufacturing technology, BioSmart Technology, allows to produce these allogeneic progenitor cell products. The company’s products are primarily used in FDA-approved clinical trials in the US and are also supplied to international regulatory agencies for clinical trials. Stemedica collaborates with ThermoFisher Scientific for the distribution of its progenitor cells. The company operates primarily in the US. Stemedica is headquartered in San Diego, California, the US.

For a complete picture of Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.